Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Clinical evidence

FORTIFI-FLEX

32 evidence topics · 10 sources

Objective
Location and study date
Study dates in the ClinicalTrials.gov record
Study characteristicQuoted record
Study start (estimated)“2026-09”
Primary completion (estimated)“2028-03”
Study completion (estimated)“2029-03”
First posted“2026-09-08”
Sites“This study has 7 locations”
Study design
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“Disease suitable for local therapy administered with curative intent.” (opens the source at this quote in a new tab)

“Prior treatment with anti-TGFβ therapy.” (opens the source at this quote in a new tab)

“Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).” (opens the source at this quote in a new tab)

“Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.” (opens the source at this quote in a new tab)

“Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.” (opens the source at this quote in a new tab)

“Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.” (opens the source at this quote in a new tab)

“Life expectancy less than 3 months.” (opens the source at this quote in a new tab)

“Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.” (opens the source at this quote in a new tab)

“Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.” (opens the source at this quote in a new tab)

“Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.” (opens the source at this quote in a new tab)

“Active autoimmune disease requiring systemic treatment in the past 2 years.” (opens the source at this quote in a new tab)

“Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.” (opens the source at this quote in a new tab)

“Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.” (opens the source at this quote in a new tab)

“Known history of human immunodeficiency virus (HIV).” (opens the source at this quote in a new tab)

“Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.” (opens the source at this quote in a new tab)

“Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.” (opens the source at this quote in a new tab)

“Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.” (opens the source at this quote in a new tab)

“Use of a live or live attenuated vaccine within 4 weeks prior to Screening.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using progression-free survival rate in the maintenance phase as the primary endpoint
Secondary endpoints in the ClinicalTrials.gov record

“Serum exposure of ficerafusp alfa.” (opens the source at this quote in a new tab)

“Objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR).” (opens the source at this quote in a new tab)

“Disease control rate (DCR) per RECIST 1.1 by blinded independent central review (BICR)” (opens the source at this quote in a new tab)

“Clinical Benefit Rate (CBR) per RECIST 1.1 by blinded independent central review (BICR)” (opens the source at this quote in a new tab)

“Duration of Response (DOR) per RECIST 1.1 by blinded independent central review (BICR).” (opens the source at this quote in a new tab)

“Progression-free survival (PFS) per RECIST 1.1 by blinded independent central review (BICR).” (opens the source at this quote in a new tab)

“Overall Survival (OS)” (opens the source at this quote in a new tab)

“Time to Response (TTR) per RECIST 1.1 by blinded independent central review (BICR)” (opens the source at this quote in a new tab)

“Deep Response Rate by blinded independent central review (BICR)” (opens the source at this quote in a new tab)

“Time to maximum tumor shrinkage” (opens the source at this quote in a new tab)

“Incidence of ≥Grade 3 TEAEs” (opens the source at this quote in a new tab)

“Incidence of Serious adverse events (SAEs)” (opens the source at this quote in a new tab)

“Incidence of Adverse events (AEs) leading to dose modifications (dose reduction, interruption, dose held, or discontinuation)” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

FORTIFI-FLEX is open-label, with no masking. Randomization occurs only after the 12-week loading phase and includes only participants without progression, so the randomized comparison addresses maintenance dosing in that subset. Both arms receive ficerafusp alfa with pembrolizumab. The primary endpoint, the proportion of maintenance-phase participants alive and progression-free at approximately 9 months, is assessed by BICR. Planned enrollment is 160 participants, and no results have been reported.